Shares of Enovis Co. (NYSE:ENOV - Get Free Report) have received an average rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $67.00.
A number of equities research analysts recently commented on the stock. Evercore ISI decreased their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research report on Tuesday, October 1st. JMP Securities began coverage on Enovis in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price target for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th.
View Our Latest Stock Analysis on Enovis
Several hedge funds and other institutional investors have recently bought and sold shares of ENOV. Ridgewood Investments LLC acquired a new stake in shares of Enovis during the 2nd quarter valued at about $44,000. DekaBank Deutsche Girozentrale purchased a new position in Enovis during the third quarter worth approximately $55,000. Innealta Capital LLC purchased a new stake in shares of Enovis in the second quarter valued at approximately $65,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock valued at $76,000 after buying an additional 371 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after buying an additional 484 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.
ENOV opened at $46.14 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -21.07 and a beta of 1.94. Enovis has a 12 month low of $38.27 and a 12 month high of $65.03. The stock has a fifty day moving average price of $44.26 and a 200-day moving average price of $44.62.
Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period in the previous year, the company posted $0.56 earnings per share. The firm's revenue was up 21.0% on a year-over-year basis. As a group, equities research analysts anticipate that Enovis will post 2.79 earnings per share for the current fiscal year.
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.